As a result, the use of PGT may be less urgent for CDKN2A PV carriers compared to individuals with hereditary cancer syndromes that involve burdensome preventive measures and surveillance methods and. This evidence concerns the gene CDKN2A and Inherited cancer-predisposing syndrome.